Variations in serum alkaline DNase activity: a possible clinical test for therapeutic prognosis of human tumors.
Previously published histochemical observations indicated that variations in serum alkaline DNase activity (SADA) could be considered as a possible prognostic test for human tumor therapy. In more than 80 cancer patients biochemical measurements of SADA were performed using the spectrophotometrical technique. A decrease of SADA promptly after the beginning of tumor treatment (phase I) may be interpreted as an early sign of therapeutically induced tumor necrosis and as a positive response to the treatment. A delayed regain of SADA (phase II) can predict the long term evolution of the disease. In this phase (II), a regain of SADA up to values higher than the initial value corresponds to a complete tumor regression. If the regain is limited to values lower than the initial value, only a partial tumor regression is seen. No variations of SADA were observed in patients without therapeutic response and with fatal evolution.
Taper
H
H
Lans
M
M
Economidou-Karaoglou
A
A
de Gerlache
J
J
Roberfroid
M
M
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy; D004796:Clinical Enzyme Tests; D003851:Deoxyribonucleases / Q000097:blood*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000175:diagnosis / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy; D009369:Neoplasms / Q000175:diagnosis*; D011379:Prognosis
D003851:Deoxyribonucleases